The company is implementing a plan to conserve capital while it pursues a pathway to regulatory approval for Cylembio and works to complete ongoing studies. The company currently has capital to run its operations into the first quarter of 2026 and is restructuring to reduce the company’s ongoing expense structure. The company expects to incur a non-recurring charge of between $1.0 – $1.5 million in the third quarter of 2025 related to the restructuring, which includes an approximate 50 percent reduction in full-time employees.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOBT:
- IO Biotech Reports Q2 2025 Financial Results
- IO Biotech’s Cylembio Shows Promise Despite Missed Endpoint, Buy Rating Affirmed
- Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech
- IO Biotech Reveals Phase 3 Trial Results for Cylembio
- IO Biotech says statistical significant missed on primary endpoint for Cylembio